CLINICAL IMPACT BY 24 MONTHS ACCORDING TO BCR/ABL1 TRANSCRIPT LEVEL AT 3 AND 6 MONTHS IN NEWLY DIAGNOSED CHRONIC PHASE CHRONIC MYELOID LEUKEMIA PATIENTS TREATED WITH RADOTINIB 300MG BID OR IMATINIB

  • Do, Y. R.; 
  • Kwak, J. -Y.; 
  • Kim, H.; 
  • Kim, J. -A.; 
  • Kim, H. J.; 
  • ... Park, J.; 
  • 외 18명
Citations

WEB OF SCIENCE

0
제목
CLINICAL IMPACT BY 24 MONTHS ACCORDING TO BCR/ABL1 TRANSCRIPT LEVEL AT 3 AND 6 MONTHS IN NEWLY DIAGNOSED CHRONIC PHASE CHRONIC MYELOID LEUKEMIA PATIENTS TREATED WITH RADOTINIB 300MG BID OR IMATINIB
저자
Do, Y. R.; Kwak, J. -Y.; Kim, H.; Kim, J. -A.; Kim, H. J.; Park, J. S.; Chung, J. S.; Shin, H. -J.; Kim, S. -H.; Kim, D. -Y.; Bunworasate, U.; Choi, C. W.; Comia, N. S.; Zang, D. Y.; Oh, S. J.; Jootar, S.; Reksodiputro, A. H.; Lee, W. S.; Mun, Y. -C.; Kong, J. H.; Caguioa, P. B.; Park, J.; Jung, C. W.; Kim, D. -W.
발행일
2017-06
유형
Meeting Abstract
저널명
Haematologica
권
102
페이지
441 ~ 441